Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicEBR:ABLX
Date11/2007
Raised
Post IPO Valuation

General Information

Offices

Ghent/Zwijnaarde, BEL
Technologiepark 21
Ghent/Zwijnaarde, 9052, BEL

People

Chairman of the Board
CFO
VP Human Resources
VP Intellectual Property & Legal
Board Member
Chairman & CEO
Board memeber
Board memeber
Show All People

Funding

POST IPO FUNDING
Post IPO Equity, 2/2013
€31.5M

Tags

Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Recent Milestones

Videos

Screenshots

Ablynx screenshot
Above: Homepage
Uploaded: 3/4/13

Stock Price

Sources

  1. ABLYNX SUCCESSFULLY RAISES €31.5 MILLION, IN TOTAL €45 MILLION PLACED (hugin.info) [edit]
  2. Ablynx lands $840M AbbVie deal on next-gen Humira successor (fiercebiotech.com) [edit]
Edit This Page
Last Edited 12/12/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy